Michelino De Laurentiis
Overview
Explore the profile of Michelino De Laurentiis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
4153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berton Giachetti P, Morganti S, Gandini S, Giudici F, Marra A, Nicolo E, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2461067.
PMID: 39982725
Importance: Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) agents is the standard first-line treatment for patients with hormone receptor-positive, ERBB2 (formerly HER2 or HER2/neu)-negative metastatic breast cancer....
2.
Glovi A, Miglione A, Maresca D, Somma F, Romano B, Ianaro A, et al.
Anal Chim Acta
. 2025 Feb;
1342:343669.
PMID: 39919857
Background: Hydrogen Sulfide (H₂S) is a biologically active endogenous gas, produced in mammalian tissues, which plays a critical role in several pathophysiological processes, including oncogenesis. This gas-transmitter can exert diametrically...
3.
Arecco L, Blondeaux E, Bruzzone M, Arpino G, De Angelis C, De Laurentiis M, et al.
J Natl Cancer Inst
. 2025 Feb;
PMID: 39908473
Background: The monarchE and NATALEE trials employed different high-risk inclusion criteria. Main objective is to assess prognostic differences based on their inclusion criteria. Methods: Patients with hormone receptor-positive/HER2-negative early breast...
4.
Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):22.
PMID: 39843642
Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab...
5.
Buono G, Capozzi M, Caputo R, Lauro V, Cianniello D, Piezzo M, et al.
Cancer Treat Rev
. 2025 Jan;
133:102868.
PMID: 39798230
Within the expanding therapeutic landscape for breast cancer (BC), metastatic breast cancer (MBC) remains virtually incurable and tend to develop resistance to conventional treatments ultimately leading to metastatic progression and...
6.
Mazzarotti G, Cuomo M, Ragosta M, Russo A, DAngelo M, Medugno A, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769237
Targeting DNA damage response (DDR) pathways represents one of the principal approaches in cancer therapy. However, defects in DDR mechanisms, exhibited by various tumors, can also promote tumor progression and...
7.
von Arx C, Calderaio C, Calabrese A, Marciano B, Martinelli C, Lauro V, et al.
Front Oncol
. 2025 Jan;
14:1447508.
PMID: 39749036
The advent and success of new drugs for treating HER2-positive metastatic breast cancer has led to a constant improvement in disease and progression-free survival as well as overall survival. Despite...
8.
Cucciniello L, Blondeaux E, Bighin C, Gasparro S, Russo S, Dri A, et al.
NPJ Breast Cancer
. 2024 Dec;
10(1):105.
PMID: 39695115
This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the...
9.
Caltavituro A, Buonaiuto R, Salomone F, Pecoraro G, Martorana F, Lauro V, et al.
Crit Rev Oncol Hematol
. 2024 Nov;
206:104577.
PMID: 39613237
The advent of immune checkpoint inhibitors (ICIs) has deeply reshaped the therapeutic algorithm of triple-negative breast cancer (TNBC). However, there is considerable scope for better engagement of the immune system...
10.
Buonaiuto R, Caltavituro A, Tafuro M, Longobardi A, Pavone G, De Santis P, et al.
Breast
. 2024 Nov;
79:103833.
PMID: 39579620
Background: The combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative...